Inactive Instrument

NTN Buzztime, Inc. Stock price

Equities

NTN

US6294106066

Broadcasting

Dynamic Chart
EGames.com Holdings LLC completed the acquisition of Social entertainment, customer engagement, and advertising technology assets of NTN Buzztime, Inc.. CI
Brooklyn ImmunoTherapeutics LLC completed the acquisition of NTN Buzztime, Inc. in a reverse merger transaction. CI
NTN Buzztime : Plans 1-for-2 Reverse Stock Split Prior to Merger; Shares Down 12% in Late Trading MT
NTN Buzztime : Obtains Shareholder Approval for Brooklyn ImmunoTherapeutics Merger MT
NTN Buzztime, Inc. has Changed its Name to Brooklyn ImmunoTherapeutics, Inc CI
Ntn Buzztime, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
NTN Buzztime : Earnings Flash (NTN) NTN BUZZTIME Reports Q3 Revenue $1.5M MT
Ntn Buzztime, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
EGames.com Holdings LLC entered into an asset purchase agreement to acquire Social entertainment, customer engagement, and advertising technology assets of NTN Buzztime, Inc. for $2 million. CI
NTN Buzztime, Inc. announced that it expects to receive $1 million in funding from eGames.com Holdings LLC CI
NTN Buzztime to Consider Options of Its Assets CI
Brooklyn ImmunoTherapeutics LLC entered into the non-binding letter of intent to acquire NTN Buzztime, Inc. for approximately $170 million in a reverse merger transaction. CI
Sean Gordon Provides Information to the Shareholders CI
Transcript : NTN Buzztime, Inc., Q1 2020 Earnings Call, May 19, 2020
NTN Buzztime, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2020 CI
More news
Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.
More about the company
  1. Stock
  2. Equities
  3. Stock NTN Buzztime, Inc. - Nyse